HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders
January 25 2022 - 8:07AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, announces
that HonorHealth has established a robotic electrophysiology
program as part of its Cardiovascular Center of Excellence at
HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona.
HonorHealth is among the first in the nation to offer the Genesis
Robotic Magnetic Navigation (RMN) system to patients receiving
minimally invasive cardiac ablation procedures.
“Establishing a robotic electrophysiology
program allows us to offer improved care for patients, furthering
our guiding vision to build a preeminent Cardiovascular Center of
Excellence at HonorHealth,” said Dr. Rahul Doshi, chief of complex
arrhythmia management. “I have closely followed the evolution of
technologies in our field and am excited by the promise of robotics
to positively transform electrophysiology for patients, physicians
and health systems.”
Robotic Magnetic Navigation introduces the
benefits of robotic precision and safety to cardiac ablation, a
common, minimally invasive procedure to treat arrhythmias. Tens of
millions of individuals worldwide suffer from arrhythmias –
abnormal heart rhythms that result when the heart beats too
quickly, too slowly, or with an irregular pattern. When left
untreated, arrhythmias may significantly increase the risk of
stroke, heart failure, and sudden cardiac arrest.
“Adopting this robotic system reflects
HonorHealth’s commitment to providing patients the most advanced
technologies and treatment options,” said Dr. Maulik Shah,
executive director of the HonorHealth Destination Center of
Excellence and cardiovascular service line. “Countless individuals
in Scottsdale and the greater Phoenix region are affected by
irregular heartbeats. HonorHealth continues to invest in addressing
the unmet medical needs in our community.”
“We are delighted to work with HonorHealth” said
David Fischel, chairman and CEO of Stereotaxis. “We applaud their
leadership and look forward to supporting their efforts to improve
patient care, advance clinical science, and build a preeminent
heart rhythm program.”
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2024 to May 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From May 2023 to May 2024